ALT-2074 is one of the company’s lead compounds under development for use in cardiovascular disease.
Noah Berkowitz, president and CEO of Synvista Therapeutics, said: “We have identified sites in Israel to perform a planned Phase II clinical trial for plaque psoriasis beginning mid-2008, pending approval from the Ministry of Health in Israel. Based on our current timeline, assuming timely receipt of regulatory approval, we hope to announce study results in the fourth quarter of 2008.”